BACKGROUND: Mast cells (MC) are multifunctional effector cells of the immune system. They derive from uncommitted CD34(+) hemopoietic progenitor cells (HPC). Depending on the stage of maturation and the environment, MC variably express differentiation- and activation-linked antigens. Little is known, however, about the regulation of expression of such antigens in immature human MC. METHODS: We analyzed expression of CD antigens on human MC grown from cord blood-derived CD34(+) HPC. The HPC were isolated by magnetic cell sorting (MACS) and FACS to >97% purity, and were cultured in stem cell factor (SCF) and interleukin (IL)-6 with or without additional cytokines (IL-4 or IL-10) in serum-free medium. The cell surface phenotype of MC was determined by monoclonal antibodies and flow cytometry. RESULTS: Cultured MC progenitors were found to react with antibodies against various CD antigens including CD58, CD63, CD117, CD147, CD151, CD203c, and CD172a, independent of the growth factors used and time-point investigated (days 14-42). CD116 [granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSFRalpha)] and CD123 (IL-3Ralpha) were expressed on MC precursors on day 14, but disappeared thereafter. Cultured MC did not express CD2, CD3, CD5, CD10, CD19, or CD25. Addition of IL-10 to MC cultures showed no effect on expression of CD antigens. However, IL-4 was found to promote expression of CD35 and CD88 on cultured MC without changing expression of other CD antigens. CONCLUSIONS: Most MC antigens may already be expressed at an early stage of mastopoiesis. Whereas IL-3R and GM-CSFRs are lost during differentiation of MC, these cells may acquire complement receptors (CD35, CD88) under the influence of distinct cytokines.
BACKGROUND: Mast cells (MC) are multifunctional effector cells of the immune system. They derive from uncommitted CD34(+) hemopoietic progenitor cells (HPC). Depending on the stage of maturation and the environment, MC variably express differentiation- and activation-linked antigens. Little is known, however, about the regulation of expression of such antigens in immature human MC. METHODS: We analyzed expression of CD antigens on human MC grown from cord blood-derived CD34(+) HPC. The HPC were isolated by magnetic cell sorting (MACS) and FACS to >97% purity, and were cultured in stem cell factor (SCF) and interleukin (IL)-6 with or without additional cytokines (IL-4 or IL-10) in serum-free medium. The cell surface phenotype of MC was determined by monoclonal antibodies and flow cytometry. RESULTS: Cultured MC progenitors were found to react with antibodies against various CD antigens including CD58, CD63, CD117, CD147, CD151, CD203c, and CD172a, independent of the growth factors used and time-point investigated (days 14-42). CD116 [granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSFRalpha)] and CD123 (IL-3Ralpha) were expressed on MC precursors on day 14, but disappeared thereafter. Cultured MC did not express CD2, CD3, CD5, CD10, CD19, or CD25. Addition of IL-10 to MC cultures showed no effect on expression of CD antigens. However, IL-4 was found to promote expression of CD35 and CD88 on cultured MC without changing expression of other CD antigens. CONCLUSIONS: Most MC antigens may already be expressed at an early stage of mastopoiesis. Whereas IL-3R and GM-CSFRs are lost during differentiation of MC, these cells may acquire complement receptors (CD35, CD88) under the influence of distinct cytokines.
Authors: Tanya M Laidlaw; John W Steinke; Adrienne M Tiñana; Chunli Feng; Wei Xing; Bing K Lam; Sailaja Paruchuri; Joshua A Boyce; Larry Borish Journal: J Allergy Clin Immunol Date: 2011-02-01 Impact factor: 10.793
Authors: J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao Journal: Leukemia Date: 2012-05-03 Impact factor: 11.528
Authors: Isaac O Onkanga; Rachael Hamilton; Pauline N M Mwinzi; Thomas Schneider; Bartholomew N Ondigo; Huldah Sang; Edna Ondari; Fredrick Rawago; Walter Jaoko; Maurice R Odiere; Lisa Ganley-Leal Journal: Infect Immun Date: 2022-07-06 Impact factor: 3.609
Authors: Bettina Sprinzl; Georg Greiner; Goekhan Uyanik; Michel Arock; Torsten Haferlach; Wolfgang R Sperr; Peter Valent; Gregor Hoermann Journal: Int J Mol Sci Date: 2021-02-28 Impact factor: 5.923
Authors: Dean D Metcalfe; Ruby Pawankar; Steven J Ackerman; Cem Akin; Frederic Clayton; Franco H Falcone; Gerald J Gleich; Anne-Marie Irani; Mats W Johansson; Amy D Klion; Kristin M Leiferman; Francesca Levi-Schaffer; Gunnar Nilsson; Yoshimichi Okayama; Calman Prussin; John T Schroeder; Lawrence B Schwartz; Hans-Uwe Simon; Andrew F Walls; Massimo Triggiani Journal: World Allergy Organ J Date: 2016-02-11 Impact factor: 4.084
Authors: Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Petri T Kovanen; Emir Hadzijusufovic; Irina Sadovnik; Hans-Peter Horny; Michel Arock; Lawrence B Schwartz; K Frank Austen; Dean D Metcalfe; Stephen J Galli Journal: Theranostics Date: 2020-08-29 Impact factor: 11.556